Weinberg Group

From Wikipedia, the free encyclopedia
Jump to: navigation, search
The Weinberg Group Inc.
Industry Food and Drug Administration
Medical Devices
Founded 1983
Headquarters Washington, DC, USA
Key people
Matthew Weinberg, CEO
Products Food and drug regulatory consulting for pharmaceutical, biotech and medical device companies
Number of employees
~ 50
Website http://www.weinberggroup.com/

The Weinberg Group is a Washington, DC-based food and drug regulatory consulting group. Founded in 1983, the firm assists pharmaceutical and biotech companies with the "development and implementation of successful and innovative regulatory strategies" and also helps these companies to "remediate, maintain and improve their regulatory compliance."[1]

BPA congressional investigation[edit]

In February 2008, John D. Dingell (D-MI) and Bart Stupak (D-MI) of the United States House of Representatives announced that their ongoing investigation into Bisphenol A (BPA) had broadened to include The Weinberg Group.[2] In March 2008, ABC News reported that the U.S. Congress was investigating the Weinberg Group. Representative John Dingell said, "The tactics apparently employed by the Weinberg Group raise serious questions about whether science is for sale at these consulting groups, and the effect this faulty science might have on the public health."[3] The House Energy and Commerce Committee, which Dingell chairs, asked the firm for records of its work on Bisphenol A and other chemicals. Some studies indicate that Bisphenol A, which is present in a wide range of plastics, is an endocrine disruptor and "can disrupt hormone systems in laboratory animals and possibly increase the risk of cancer or other serious illness."[4] Canada and 10 U.S. state have moved to ban the chemical from baby bottles,[3] and in February the U.S. National Toxicology Program released a report concluding that "there is some concern for neural and behavioral effects in fetuses, infants, and children at current human exposures," and that "bisphenol A exposure in these populations based on effects in the prostate gland, mammary gland, and an earlier age for puberty in females."[5]

According to the Center for Science in the Public Interest the committee also "accused the firm of generating false uncertainty about scientific research that cast a negative light on their clients’ products. After showing deleted pages from the Weinberg Group's website boasting about its work for two pharmaceutical clients, the committee demanded the firm hand over documents naming the drug, the drug manufacturer and the experts used to prevent the drug’s ban. The group has also been accused of working to cast doubt on research linking a brand name hair dye to cancer and the impact of chlorofluorocarbons on the ozone layer."[6]

The U.S. Congress investigated statements that allegedly appeared on the firm's website claiming that it successfully kept on sale, for 10 years, a drug that was eventually cancelled as harmful.[7]

In response CEO Matthew Weinberg issued a statement saying "The analyses we conduct are rigorous and adhere to established principles of scientific integrity […] We believe it is in the public interest for all scientific research to be subject to scrutiny and the views of all affected parties to be heard."[3]


The Weinberg Group has consulted for a number of pharmaceutical, chemical, and tobacco companies. Chemicals that the Group has worked on include trichloroethylene (TCE),[8] Teflon (see below), PCBs,[9] Bisphenol A, and the organochlorine insecticide endosulfan.[10] In 2007, The Weinberg Group was a sponsor of the International Society of Regulatory Toxicology & Pharmacology,[11] a group described as "an association of dominated by scientists who work for industry trade groups and consulting firms," by David Michaels.[12] Since 2006, The Weinberg Group has been a sponsor of The Washington Legal Clinic for the Homeless event – Lawyer's Pitch In. The Washington Legal Clinic for the Homeless is described as providing legal services to people facing homelessness in DC.[13]

DuPont and perfluorooctanoic acid[edit]

In an article authored by Paul D. Thacker, Environmental Science & Technology reported that in April 2003, the Weinberg Group proposed a strategy to DuPont to help defuse the growing controversy over the health impacts of perfluorooctanoic acid (PFOA), a compound used to make Teflon. Weinberg's Vice-President of Product Defense, P. Terrence Gaffney, wrote, "DuPont must shape the debate at all levels." One of his suggested strategies was to facilitate the "publication of papers and articles dispelling the alleged nexus between PFOA and teratogenicity as well as other claimed harm."[14]

Gaffney also proposed to "develop 'blue ribbon panels' of thought leaders on issues related to PFOA" and to "coordinate the publishing of white papers on PFOA, junk science and the limits of medical monitoring." DuPont confirmed that they had hired the Weinberg Group to help with "scientific third party experts." The five-page 2003 letter also states that the Weinberg Group "has helped numerous companies manage issues allegedly related to environmental exposures. Beginning with Agent Orange in 1983, we have successfully guided clients through myriad regulatory, litigation and public relations challenges posed by those whose agenda is to grossly over regulate, extract settlements from, or otherwise damage the chemical manufacturing industry."[14]

Alcohol industry[edit]

In an editorial that ran in the British Medical Journal, Martin McKee, a professor of public health at the London School of Hygiene and Tropical Medicine, criticized the Weinberg Group for writing a white paper on alcohol regulation for the European alcohol industry. "Its approach is remarkably similar to the tobacco industry reports, contending that there is insufficient evidence that alcohol causes as much harm as is alleged or that preventive measures would be effective."[15]

Tobacco industry[edit]

The Weinberg Group has also worked closely with the tobacco industry. Myron Weinberg, and the company bearing his name, have been acting as tobacco industry consultants, in particular for Philip Morris.[16][17] Myron Weinberg is listed in a Philip Morris grants and projects budget as being paid $50,000 U.S.D. in 1995 alone for "Consulting Related to ETS Projects." [18] Philip Morris budgeted $250,000 for the Weinberg Group for Feb–Dec 1998 to organize a risk management conference and help develop and publicize a body of academic literature on risk management.[19]

The Weinberg Group also assisted the tobacco industry's law firm, Covington & Burling, with implementing a multinational Environmental Tobacco Smoke scientific witness program (also known as the "Whitecoat Project.") A Covington & Burling internal document dated 1988 claims the purpose of the meeting was "to discuss ETS as a public affair as well as a scientific issue – and to begin discussion of the role that consulting scientists can play in promoting an objective understanding of the issue among members of the scientific community, government officials and members of the public."[20]

Building STEPS[edit]

Building STEPS is a private non-profit organization, founded in 1995 by Matthew Weinberg, CEO of The Weinberg Group, that was developed to expose bright, underserved students to professions that rely on science and technology and to help them excel in these fields where minorities are overwhelmingly underrepresented. Headquartered in Baltimore, Maryland since 1999, 90% of the students graduating from this two-year, academic and professional development program matriculate to college.[21]


  1. ^ Weinberg Group Homepage, Accessed June 24, 2014.
  2. ^ http://energycommerce.house.gov/index.php?option=com_content&task=view&id=371&Itemid=1
  3. ^ a b c Layton, Lyndsey (April 27, 2008). "Studies on Chemical In Plastics Questioned Congress Examines Role Of Industry in Regulation". Washington Post. pp. A1. .
  4. ^ Justin Rood, "Congress: Science for Sale? Congress Launches Probe Into Firm's Work on Chemical Used to Make Many Plastic Bottles," ABC News, February 6, 2008.
  5. ^ Since you asked – Bisphenol A: Questions and Answers about the Draft National Toxicology Program Brief on Bisphenol A, National Institute of Environmental Health Sciences website.
  6. ^ CSPI Integrity in Science Watch Week of March 17, 2008
  7. ^ Science for Sale Probe Deepens, Justin Rood, ABC News, MArch 11, 2008.
  8. ^ Lamb JC, Hentz KL (November 2006). "Toxicological review of male reproductive effects and trichloroethylene exposure: assessing the relevance to human male reproductive health". Reprod. Toxicol. 22 (4): 557–63. doi:10.1016/j.reprotox.2006.07.001. PMID 16938429. Retrieved April 30, 2008. 
  9. ^ Nichols BR, Hentz KL, Aylward L, Hays SM, Lamb JC (November 2007). "Age-specific reference ranges for polychlorinated biphenyls (PCB) based on the NHANES 2001–2002 survey". J. Toxicol. Environ. Health Part A 70 (21): 1873–7. doi:10.1080/15287390701457688. PMID 17934961. Retrieved April 30, 2008. 
  10. ^ "Endosulfan's Occupational Risk Assessment Evaluation of EPA's proposed Aggregation of Dermal Inhalation Exposure." The Weinberg Group, sponsored by Makhteshim Agan of North America. Document ID No. EPA-HQ-OPP-2002-0262-0098.7, accessible via www.regulations.gov.
  11. ^ [1]
  12. ^ Michaels, David (2008). Doubt Is Their Product: How Industry's Assault on Science Threatens Your Health. New York: Oxford University Press. ISBN 978-0-19-530067-3. 
  13. ^ http://www.legalclinic.org/donors/lpi.asp
  14. ^ a b Paul D. Thacker. (February 22, 2006). The Weinberg proposal. Environ. Sci. Technol., Feb 22, 2006. doi:10.1021/es0630137
  15. ^ Martin McKee "A European Alcohol Strategy: Will the opportunity be missed?", British Medical Journal, October 17, 2006.
  16. ^ Philip Morris Privilege Log, Glossary of Names; the Weinberg Group is described by Philip Morris as "Consultants for Philip Morris" and Myron Weinberg is described as "Weinberg Consulting Group, Philip Morris Outside Litigation Consultants (sic!)"
  17. ^ Ong EK, Glantz SA (2000). "Tobacco industry efforts subverting International Agency for Research on Cancer's second-hand smoke study". Lancet 355 (9211): 1253–9. doi:10.1016/S0140-6736(00)02098-5. PMID 10770318. 
  18. ^ Legacy Tobacco Documents Library: EXHIBIT E RESEARCH (GRANTS & PROJECTS 45... (yfm19c00)
  19. ^ Legacy Tobacco Documents Library: TECHNICAL PROJECT / AVTIVITY SUMMARY (jcu18d00)
  20. ^ http://legacy.library.ucsf.edu/tid/cjk49e00/pdf
  21. ^ http://www.buildingsteps.org/pdfs/BaltimoreMagazine_9-1-2008.pdf

External links[edit]